Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-03-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancerher2negativeto assesstherapy
  Phrases that lowered it: jointskinclinicalamericanaccording
• Sponsor's past termination rate: 17.3% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 26 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 9.6% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 46315 (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 8248 (lowers risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Disease area, dermatology: Yes (raises risk) · Disease area
• Keywords listed: 9 (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports marked serious: 74.0% (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Allocation: not applicable (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer NCT05150652 · started 2022 · scored riskier than 87% of active trials completed
• Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients NCT01972984 · started 2012 · scored riskier than 74% of active trials completed
• Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy NCT00661531 · started 2008 · scored riskier than 58% of active trials terminated
• Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. NCT00921115 · started 2009 · scored riskier than 99% of active trials completed
• Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer NCT03747042 · started 2018 · scored riskier than 94% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.